A Phase II Pharmacologic and Biologic Study of Escalating Doses of Thalidomide (NSC #66847) Administered Orally Once a Day in Combination With a Fixed Dose of SU5416 (NSC #696819) [semaxanib] in Patients With Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2007
At a glance
- Drugs Semaxanib (Primary) ; Thalidomide
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Oct 2007 Status changed from in progress to completed.
- 29 Sep 2005 New trial record.